On April 11, 2022 PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoantigen-specific T cell receptor (neoTCR) T cell therapies for the eradication of solid tumors, reported that new data highlighting several aspects of its first-of-its-kind personalized neoantigen platform for adoptive cell therapies were presented in five separate poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 (Press release, PACT Pharma, APR 11, 2022, View Source [SID1234612018]). The breadth of presented data reflects the expansive collection of pioneering insights into patient-specific TCR repertoires against solid tumors that the company has been able to accumulate through analysis of research samples, as well as patient samples from its ongoing first-in-human Phase 1 trial. The AACR (Free AACR Whitepaper) conference is being held April 8-13, 2022, in New Orleans, Louisiana.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The scope of presented findings at AACR (Free AACR Whitepaper) highlights the significant progress that we have made across all aspects of our unique neoTCR T cell therapy platform, spanning identification and verification of patient-specific tumor driving mutations, gene editing, cell manufacturing, machine learning and bioinformatics," said Stefanie Mandl, Ph.D., senior vice president, head of research at PACT Pharma. "This continued progress speaks to the dynamic research and development approach that we are undertaking at PACT, as we aggressively advance our clinical-stage assets in human studies while using the evolving data set and learnings from our Phase 1 trial to continue to enhance various aspects of our technology platforms. This constellation of activities is focused on the single goal of bringing much needed, first-of-its kind neoTCR T cell therapies to patients battling solid tumors."
PACT is currently conducting a Phase 1 clinical trial evaluating the safety, tolerability and feasibility of adoptive cell therapy with its non-viral PACT^NV gene-edited autologous neoTCR T cells in advanced and metastatic solid tumors. This trial, in combination with extensive preclinical studies, has provided the company with unique data sets and insights derived from the core technologies that comprise its personalized adoptive T cell therapy platform for the treatment of solid tumors.
Key presented findings at AACR (Free AACR Whitepaper) included:
imPACT Isolation Technology Platform for TCR Discovery and Validation: Identifies TCRs to Patient-Specific Tumor Driver Mutations
By applying its imPACT Isolation Technology platform to peripheral blood samples of more than 170 patients with solid tumors, PACT generated key findings on the relative distribution of patient-private mutations versus mutations in known cancer driver genes. Data demonstrated that tumor-specific T cells preferentially recognize patient-private mutations. However, TCRs that target known cancer driver mutations were shown to constitute > 5% of the functionally characterized TCRs, highlighting a high-value opportunity for "off-the-shelf" TCR therapies. Based on these findings, PACT is expanding its platform to develop such "off-the-shelf" treatments, and anticipates filing an investigational new drug (IND) application in the second half of 2022.
Proprietary Machine Learning and Bioinformatics Optimize Personalized Treatment Strategies
In two separate AACR (Free AACR Whitepaper) posters, PACT highlighted its continued work building and utilizing its PACTImmune Database with extensive pre-, on- and post-treatment data from its ongoing Phase 1 trial. Analysis of this maturing data set with proprietary machine learning and bioinformatics produced new insights into patient-specific tumor immunogenicity in solid cancers, providing opportunities to optimize personalized neoTCR T cell treatment. The company’s application of its proprietary PACT-ESCAPE technology provided key learnings regarding neoepitope presentation escape mechanisms, which is a critical aspect of personalized TCR-based immunotherapy.
PACT^NV: Efficiently Enabling Single-Step Precision Gene Editing
In two separate poster presentations, PACT reported continued progress with PACT^NV, the company’s non-viral precision gene editing approach for generating clinical-grade TCR T cells for adoptive cell therapy. Importantly, the company has demonstrated the ability to execute precise, time-efficient, single-step gene editing to simultaneously knock-out TCR genes and insert neoantigen-specific TCRs isolated from a patient’s own blood. Furthermore, the company described its success incorporating additional complex modifications, which are intended to address challenges presented by the immunosuppressive nature of some tumor microenvironments, into the single-step gene editing process.
Copies of the posters presented at the AACR (Free AACR Whitepaper) conference are available on the "Events" page of the PACT Pharma website at: View Source